Replies to post #1342 on About StemCells, Biomedicine, Diet Impact, Mental

[BottomBounce]

$AMRS & Biogen. $BIIB Collaboration $300+ #Biotech Stock Amyris recently announced partnership with Biogen, Inc. to develop alternative cell lines supporting production of therapeutics, marking second major partnership in biopharma market, which is now positioned to become Amyris’s largest opportunity for collaborations. The Biogen partenrship is the most exciting of all,” CEO John Melo said,. With it, Amyris he said would make “ a transformative change to biopharma where partner would be able to employ [Amyris biotechnology] instead of using cells from mammals. Others have attempted and failed, but we are positioned to deliver life saving therapeutics and make them more widely available. This could be game changing for biopharmaceuticals, and Biogen will fully fund the development.”
http://www.biofuelsdigest.com/bdigest/2016/08/14/amyris-the-new-colossus-aims-to-unlock-its-golden-door/

[BottomBounce]

$AMRS "Amyris’s µPharm™ discovery and production platform opens up new possibilities for drug discovery using proven synthetic biology to create compound libraries containing natural and natural product-like compounds in a scalable production organism.
Create – Discover – Deliver

Using a combinatorial rational design process and proprietary yeast strains and strain engineering technology for production of terpenoids, Amyris scientists build libraries of microorganisms that produce natural and novel compounds of pharmaceutical relevance. These compounds were previously difficult or impossible to obtain through traditional chemical synthesis.

These libraries can be generated in strains engineered to allow detection or selection of ligands with affinity to defined pharmaceutical targets. Once yeast strains with lead compounds are identified, the same combination of heterologous genes can be transferred into a yeast host optimized for terpenoid production at pilot or commercial scales.
Benefits

Nearly half of all drugs approved since 1994 are based on compounds present in natural products.
Many pharmaceutical companies have reduced or eliminated natural product drug discovery screening due to difficulties in access, complexities of natural product chemistry and purification, and challenges in supply.
There are over 30,000 known terpenoids in nature, and many terpenoid and terpene-derived molecules are biologically active signaling agents.
Amyris has developed a state-of-the-art platform for generating and screening diversity based on over a decade of experience in producing terpenoids.
Using combinatorial design, Amyris can produce more than 100,000 novel terpenoids derived from natural terpene scaffolds."
https://amyris.com/collaborations/%CE%BCpharm/